摘要
目的评价以不同剂量西艾克（VDS）为主治疗晚期癌的疗效和毒性。方法1993年4月至1997年8月，147例患者分A组（治疗组）：VDS1．4mg／m2／d×3天为主的联合化疗组83例；B组（对照组）：VDS2．5～3mg／m2，第1、8天为主的联合化疗组64例。两组3～4周为一周期，2～3周期为一疗程，VDS每例疗程总量A组12～18mg，B组16～24mg。疗效和毒性用卡方检验。结果A组有效率50．6％（42／83），CR期2～10个月，PR期1～4月；B组有效率50．0％（32／64），CR期3～9个月，PR期1～3．5个月。两组疗效比较差异无显著性（P＞0．05）．毒性反应相似（P＞0．05），均可耐受。结论不同剂量VDS为主治疗非霍奇金淋巴瘤，乳腺癌,小细胞肺癌，食管瘤等晚期癌均有较好疗效，在晚期癌的联合化疗中，VDS1．4mg／m2／d×3天用药和2．5～3mm／m2第1、8天用药，两种方法是可取的。
Objective To campare the therapeutic effect and toxicity of various doses of vindesine combined with multi-drug chemotherapy for advanced malignant tumours. Methods From April 1993 tO June 1997,according to various doses of vindesine, 147 patients were divided into A and B groups: A vindesine 1. 4mg/m2·d on days 1 to 3,in 83 patients j B. vindesine 2. 5～3mg/m2 on day 1 and day 8, in 64 patients. Treatment cycle were repeated at 3～4 weekly intervals, 2～3 cycles consisted a course. In group A total doses of vindesine per course were 12～18mg; in group B total doses of vindesine per course were 16～24mg. The responses and toxicities were compared by the X2 test. Results The group A and B showed a total response rate of 50. 6% (42/83) and 50. 0% (32/64) complete renlisslon 2～10 months and 3～9 months, partial remission 1～4 months and 1～3. 5 months respectively (P>0. 05 ). The toxic reactions were tolerable in both groups (P>0. 05 ). Conclusion Various doses vindesine combined with multi-drug chemotherapy for non-Hodgkins' lymphoma, breast cancer, small cell lung cancer and esophageal carcinoma, were similar in responding rate and safety.Vindesine 1. 4mg/m2.·d on days 1 to 3 was better than 2. 5～3mg/m2 on day 1 and day 8 in some patients.[
出处
《中国肿瘤临床与康复》
1999年第5期87-89,共3页
Chinese Journal of Clinical Oncology and Rehabilitation
